+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Induced Pluripotent Stem Cell (iPSC) - Global Market Trajectory & Analytics

  • ID: 4805485
  • Report
  • September 2020
  • Region: Global
  • 397 pages
  • Global Industry Analysts, Inc
1 of 2
The global market for Induced Pluripotent Stem Cell ((iPSC) is projected to reach US$1.8 billion by 2025, driven by the growing value of stem cells in medicine.

Stem cells are undifferentiated cells that hold the capability to divide, and differentiate into specialized cells in the body. Stem cells act as repair system and replenish adult tissues, maintaining the turnover of regenerative organs such as the blood and skin. In organs, such as the bone marrow, stem cells frequently form replacement cells to repair the worn out tissue. These cells can respond to signals from the body and transverse a particular developmental pathway to differentiate into one specific cell type. Due to their regenerative properties, stem cells are being researched for therapeutic applications in diabetes, cardiovascular disease, neurodegenerative disease, cancer, autoimmune diseases, spinal cord defects, among others. Stem Cell research is an exciting field where continuous discoveries are being made on new sources of stem cells and new methods of their acquisition and harvesting. Of late, adult stem cells have garnered a lion`s share of the stem cell space, purely based on the fact that they require less expensive clinical trials, need to comply with fewer regulatory norms and ethical issues compared to other stem cell variants such as embryonic stem cells. Researchers around the world have been focusing research activities to develop adult stem cell therapies in order to combat a variety of diseases ranging from diabetes to heart disease. Factually, adult stem cells are the only stem cells that have been approved for use in transplants for the treatment of diseases such as cancer. Interestingly, with drug development based on embryonic stem cells being challenged amid growing debate over ethics and regulation of this research, iPSCs offers an alternate step forward in the commercialization of stem cell therapies and regenerative medicine. Embryonic stem cell research continues to remain embroiled in ethical, religious, and political controversies across various countries around the world. Induced Pluripotent Stem Cells (iPSs), which are reprogrammed to mimic embryonic stem cell-like state allowing expression of genes and human cells needed for therapeutic purposes, offers an attractive alternate way forwarding in furthering the goals of stem cell research. Pioneered in 2006 and developed in the following year, these cells are created by conversion of somatic cells into PSCs by introducing certain genes including Myc, Klf4, Oct3/4 and Sox2.

Pluripotent stem cells hold tremendous potential in the regenerative medicine arena. Based on their ability to proliferate indefinitely and develop into desirable cell type such as heart, liver, neuronal and pancreatic cells, iPSCs offer a source of new cells that can replace lost or damaged cells. For instance, iPSCs can be developed into beta islet cells, blood cells or neuronal cells for the treatment of diabetes, leukemia and neurological disorders, respectively. Parkinson`s, Alzheimer`s & spinal cord injuries are key neurologic diseases expected to benefit from iPS research. Dramatic rise in cancer cases worldwide and the need for novel anti-cancer therapies will emerge as a key driver for the growth of iPSCs. Interest in cancer research soars high on new hopes of direct reprogramming of cancer cells with enforced expression of pluripotency factors and the resulting dedifferentiation of transformed cancer cells.

Competitors identified in this market include, among others:
  • Axol Bioscience Ltd.
  • Cynata Therapeutics Limited
  • Evotec SE
  • Fate Therapeutics, Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • Ncardia
  • Pluricell Biotech
  • Shenzhen Sanqi Biotechnology Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.
Note: Product cover images may vary from those shown
2 of 2


  • Stem Cells, Application Areas, and the Different Types: A Prelude
  • Applications of Stem Cells
  • Types of Stem Cells
  • Induced Pluripotent Stem Cell (iPSC): An Introduction
  • Production of iPSCs
  • First & Second Generation Mouse iPSCs
  • Human iPSCs
  • Key Properties of iPSCs
  • Transcription Factors Involved in Generation of iPSCs
  • Noteworthy Research & Application Areas for iPSCs
  • Induced Pluripotent Stem Cell ((iPSC) Market: Growth Prospects and Outlook
  • Drug Development Application to Witness Considerable Growth
  • Technical Breakthroughs, Advances & Clinical Trials to Spur Growth of iPSC Market
  • North America Dominates Global iPSC Market
  • Competition
  • Recent Market Activity
  • Impact of Covid-19 and a Looming Global Recession
  • Axol Bioscience Ltd. (UK)
  • Cynata Therapeutics Limited (Australia)
  • Evotec SE (Germany)
  • Fate Therapeutics, Inc. (USA)
  • FUJIFILM Cellular Dynamics, Inc. (USA)
  • Ncardia (Belgium)
  • Pluricell Biotech (Brazil)
  • Shenzhen Sanqi Biotechnology Co., Ltd. (China)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Takara Bio, Inc. (Japan)
  • Thermo Fisher Scientific, Inc. (USA)
  • ViaCyte, Inc. (USA)
  • Induced Pluripotent Stem Cells: A Giant Leap in the Therapeutic Applications
  • Research Trends in Induced Pluripotent Stem Cell Space
  • Worldwide Publication of hESC and hiPSC Research Papers for the Period 2008-2010, 2011-2013 and 2014-2016
  • Number of Original Research Papers on hESC and iPSC Published Worldwide (2014-2016)
  • Concerns Related to Embryonic Stem Cells Shift the Focus onto iPSCs
  • Regenerative Medicine: A Promising Application of iPSCs
  • Induced Pluripotent: A Potential Competitor to hESCs?
  • Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
  • Global Stem Cell & Regenerative Medicine Market by Product (in %) for the Year 2019
  • Global Regenerative Medicines Market by Category: Breakdown (in %) for Biomaterials, Stem Cell Therapies and Tissue Engineering for 2019
  • Pluripotent Stem Cells Hold Significance for Cardiovascular Regenerative Medicine
  • Leading Causes of Mortality Worldwide: Number of Deaths in Millions & % Share of Deaths by Cause for 2017
  • Leading Causes of Mortality for Low-Income and High-Income Countries
  • Growing Importance of iPSCs in Personalized Drug Discovery
  • Persistent Advancements in Genetics Space and Subsequent Growth in Precision Medicine Augur Well for iPSCs Market
  • Global Precision Medicine Market (In US$ Billion) for the Years 2018, 2021 & 2024
  • Increasing Prevalence of Chronic Disorders Supports Growth of iPSCs Market
  • Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
  • Number of New Cancer Cases Reported (in Thousands) by Cancer Type: 2018
  • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
  • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for iPSCs Market
  • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • Growth in Number of Genomics Projects Propels Market Growth
  • Genomic Initiatives in Select Countries
  • New Gene-Editing Tools Spur Interest and Investments in Genetics, Driving Lucrative Growth Opportunities for iPSCs: Total VC Funding (In US$ Million) in Genetics for the Years 2014, 2015, 2016, 2017 and 2018
  • Launch of Numerous iPSCs-Related Clinical Trials Set to Benefit Market Growth
  • Number of Induced Pluripotent Stem Cells based Studies by Condition
  • Clinical Trials with Cells Derived from Human-Induced Pluripotent Stem Cells
  • iPSCs-based Clinical Trial for Heart Diseases
  • Induced Pluripotent Stem Cells for Stroke Treatment
  • ‘Off-the-shelf’ Stem Cell Treatment for Cancer Enters Clinical Trial
  • iPSCs for Hematological Disorders
  • Market Benefits from Growing Funding for iPSCs-Related R&D Initiatives
  • Stem Cell Research Funding in the US (in US$ Million) for the Years 2011 through 2017
  • Human iPSC Banks: A Review of Emerging Opportunities and Drawbacks
  • Human iPSC Banks Worldwide: An Overview
  • Cell Sources and Reprogramming Methods Used by Select iPSC Banks
  • Innovations, Research Studies & Advancements in iPSCs
  • Key iPSC Research Breakthroughs for Regenerative Medicine
  • Researchers Develop Novel Oncogene-Free and Virus-Free iPSC Production Method
  • Scientists Study Concerns of Genetic Mutations in iPSCs
  • iPSCs Hold Tremendous Potential in Transforming Research Efforts
  • Researchers Highlight Potential Use of iPSCs for Developing Novel Cancer Vaccines
  • Scientists Use Machine Learning to Improve Reliability of iPSC Self-Organization
  • STEMCELL Technologies Unveils mTeSR™ Plus
  • Challenges and Risks Related to Pluripotent Stem Cells
  • A Glance at Issues Related to Reprogramming of Adult Cells to iPSCs
  • A Note on Legal, Social and Ethical Considerations with iPSCs















  • Total Companies Profiled: 45
Note: Product cover images may vary from those shown